Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 70 of 244 for:    "Viral Infectious Disease" | "Lopinavir"

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01049685
Recruitment Status : Unknown
Verified January 2010 by UPECLIN HC FM Botucatu Unesp.
Recruitment status was:  Active, not recruiting
First Posted : January 14, 2010
Last Update Posted : February 15, 2010
Sponsor:
Information provided by:
UPECLIN HC FM Botucatu Unesp

Brief Summary:
Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA <50 copies/mL) in the first six months and at the end of the study.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: First-line Antiretroviral Therapy Phase 4

Detailed Description:

Background: Either LPV/r or EFZ plus a two nucleoside reverse-transcriptase inhibitors (NRTIs) are recommended by the current guidelines all around the world as the main background drugs for initial therapy of human immunodeficiency virus type 1 (HIV-1) infection. This indication is based in results of clinical trials, but patients who participate in these studies usually are greatly motivated to continue their prescribed regimen, and can be different from the "real life". Therefore, clinical practice often cannot reproduce published results.

Methods: A retrospective longitudinal cohort study was performed with 36 naïve-treatment patients, who started therapy with LPV/r or EFZ, with follow-up of 36 months. The primary endpoint was virological success (HIV RNA <50 copies/mL) in the first six months and at the end of the study. Effectiveness was examined comparing time to virological failure and CD4 recovery.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study
Study Start Date : August 2006
Actual Primary Completion Date : December 2009
Estimated Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Active Comparator: Efavirenz Group
Naïve-treatment HIV patients, who started therapy with Efavirenz
Drug: First-line Antiretroviral Therapy
  • Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background
  • Efavirenz: 01 capsules day, plus NRTI background
Other Names:
  • Sustiva
  • Kaletra

Active Comparator: Lopinavir/r Group
Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
Drug: First-line Antiretroviral Therapy
  • Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background
  • Efavirenz: 01 capsules day, plus NRTI background
Other Names:
  • Sustiva
  • Kaletra




Primary Outcome Measures :
  1. Maintenance HIV RNA <50 copies/mL at the end oh 36 months [ Time Frame: 36 months ]

Secondary Outcome Measures :
  1. Achieve HIV RNA <50 copies/mL at the first 6 months [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-1 infected naive-treatment patients

Exclusion Criteria:

  • use of Anti-Retroviral Agents in the past

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01049685


Locations
Layout table for location information
Brazil
SAE e Hospital Dia Domingos Alves Meira
Botucatu, SP, Brazil, 18603-790
Sponsors and Collaborators
UPECLIN HC FM Botucatu Unesp
Investigators
Layout table for investigator information
Principal Investigator: Alexandre N Barbosa, MD, MSc Botucatu School of Medicine

Layout table for additonal information
Responsible Party: Alexandre Naime Barbosa, SAE e Hospital Dia Domingos Alves Meira - Faculdade de Medicina de Botucatu - Unesp
ClinicalTrials.gov Identifier: NCT01049685     History of Changes
Other Study ID Numbers: upeclin/HC/FMB-Unesp-38
First Posted: January 14, 2010    Key Record Dates
Last Update Posted: February 15, 2010
Last Verified: January 2010
Keywords provided by UPECLIN HC FM Botucatu Unesp:
HIV
Antiretroviral Therapy, Highly Active
Efavirenz
Lopinavir
Comparative Effectiveness Research
Treatment Naive
Additional relevant MeSH terms:
Layout table for MeSH terms
RNA Virus Infections
Virus Diseases
Lopinavir
HIV Infections
Lentivirus Infections
Retroviridae Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Ritonavir
Efavirenz
Anti-Retroviral Agents
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP3A Inducers